The CK2 inhibitor CX-4945 was also combined with selumetinib, an inhibitor of mitogen-activated protein kinase 1/2 (MEK 1/2), to treat non-small cell lung cancers, synergizing in targeting cancer cell survival, proliferation, differentiation, and migration [130]. Here, MAP2K1 is linked to cancer.